Company Overview of Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of novel therapeutics to prevent and treat cardiovascular diseases. Its lead product candidates include CAP-1002 and Cenderitide. The company was founded in 2005 and is based in Beverly Hills, California.
8840 Wilshire Boulevard
Beverly Hills, CA 90211
Founded in 2005
Key Executives for Capricor Therapeutics, Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $232.9K
Executive Vice President, General Counsel and Secretary
Total Annual Compensation: $243.8K
Vice President of Medical Affairs
Total Annual Compensation: $225.0K
Compensation as of Fiscal Year 2014.
Capricor Therapeutics, Inc. Key Developments
Capricor Therapeutics, Inc. Announces Resignation of Andrew Hamer as Vice President of Medical Affairs, Effective on or About July 30, 2015
Jul 9 15
On July 2, 2015, Capricor Therapeutics, Inc. accepted the resignation of Andrew Hamer, M.D., Vice President of Medical Affairs. Dr. Hamer's resignation will be effective on or about July 30, 2015.
Capricor Therapeutics Appoints Houman Hemmati as Vice President of Medical and Clinical Development for New Therapies
Jun 17 15
Capricor Therapeutics, Inc. announced the appointment of Houman Hemmati, M.D., Ph.D. to the newly created position of Vice President of Medical and Clinical Development for New Therapies. In this role, Dr. Hemmati will work to drive promising new therapies such as Capricor's exosome platform into clinical development as he works closely with the R&D, manufacturing and product development teams. Prior to joining Capricor, Dr. Hemmati, an ophthalmologist, was Director of Clinical Development at Allergan, where responsibilities included early to late stage clinical trial development of high profile ophthalmic products such as Restasis-X as well as Allegan's androgen based ophthalmic treatment and AGN 199201 for presbyopia. Prior to his time at Allergan, he co-founded Avicenna Pharmaceuticals in Paris, France, to advance a technology based on cancer stem cell mutations he had discovered at Caltech.
Capricor Therapeutics Announces Receipt of Food and Drug Administration Clearance for the Phase I/II Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy Related Cardiomyopathy
Jun 8 15
Capricor Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) have cleared its Investigational New Drug Application (IND) for the clinical development of CAP-1002 for the treatment of patients with Duchenne Muscular Dystrophy (DMD) related cardiomyopathy. CAP-1002 is Capricor's allogeneic, cardiosphere-derived cell (CDC) therapy already in clinical development for the treatment of heart disease. The HOPE-DUCHENNE trial is designed to enroll up to 24 patients in a randomized, multi-center study evaluating the safety and preliminary efficiency of CAP-1002. Patients will receive CAP-1002 in all three coronary arteries which will allow for it to be delivered to wide areas of the myocardium similar to that which was used earlier this year in the DYNAMIC trial.Â Previously, Capricor was granted orphan drug designation by the FDA for CAP-1002 used for the treatment of cardiomyopathy associated with DMD.
Similar Private Companies By Industry
Recent Private Companies Transactions
February 3, 2015
January 9, 2015